Glaukos Corporation (NYSE:GKOS) Receives Consensus Rating of “Moderate Buy” from Brokerages

Glaukos Corporation (NYSE:GKOS) has earned a consensus rating of “Moderate Buy” from the fourteen ratings firms that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and twelve have issued a buy recommendation on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $178.0833.

GKOS has been the topic of a number of research reports. Truist Financial raised their price target on Glaukos from $180.00 to $215.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. Wells Fargo & Company upped their price objective on Glaukos from $138.00 to $178.00 and gave the company an “overweight” rating in a research report on Thursday, July 30th. JPMorgan Chase & Co. increased their target price on Glaukos from $120.00 to $140.00 and gave the company an “overweight” rating in a report on Thursday, April 30th. Citigroup raised their target price on Glaukos from $175.00 to $188.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. Finally, BTIG Research boosted their price target on Glaukos from $193.00 to $202.00 and gave the company a “buy” rating in a research note on Thursday.

Key Stories Impacting Glaukos

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: BTIG Research raised its price target to $202 from $193 and maintained a “Buy” rating, implying additional upside from the referenced share price. The move reinforces bullish sentiment among analysts. BTIG price target report
• Positive Sentiment: Zacks Research lifted its FY2026 EPS forecast to a loss of $0.43 from a loss of $0.65, its Q3 2026 estimate to a loss of $0.13 from $0.16, and its Q4 estimate to positive $0.03 from a loss of $0.02. The revisions suggest improving near-term earnings trends.
• Positive Sentiment: Zacks also raised its FY2027 EPS estimate to $0.45 from $0.38 and its FY2028 forecast to $1.70 from $1.56. Several later-quarter estimates were increased, pointing to expectations that Glaukos will become increasingly profitable as its products scale.
• Positive Sentiment: Momentum in the iDose TR glaucoma implant and the Epioxa launch is reportedly driving record growth, higher 2026 guidance and expansion of Glaukos’ ophthalmology platform. Zacks growth outlook article
• Neutral Sentiment: Glaukos recently reported revenue of $185.6 million, up 49.6% year over year, while its $0.14 quarterly loss was narrower than expected. However, the company remains unprofitable, and its current-year consensus EPS forecast is still a loss of $0.35.
• Negative Sentiment: Director Gilbert H. Kliman sold 2,500 shares for approximately $475,000 at an average price of $190, reducing his direct ownership by 6.26%. He retained 37,406 shares, so the transaction is a modest negative signal rather than a major change in insider alignment. SEC insider selling filing

Insider Buying and Selling at Glaukos

In other Glaukos news, Director Gilbert H. Kliman sold 2,500 shares of the stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $190.00, for a total value of $475,000.00. Following the transaction, the director directly owned 37,406 shares in the company, valued at approximately $7,107,140. This trade represents a 6.26% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Alex R. Thurman sold 20,000 shares of Glaukos stock in a transaction on Friday, August 7th. The stock was sold at an average price of $180.13, for a total transaction of $3,602,600.00. Following the transaction, the chief financial officer owned 43,906 shares in the company, valued at $7,908,787.78. This represents a 31.30% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 113,025 shares of company stock worth $19,600,006. 5.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Glaukos

A number of institutional investors have recently bought and sold shares of the stock. BlackRock Inc. bought a new position in shares of Glaukos in the second quarter worth about $1,333,318,000. Jupiter Topco LLC bought a new position in shares of Glaukos during the 2nd quarter valued at approximately $679,614,000. Primecap Management Co. CA purchased a new stake in Glaukos in the 2nd quarter worth approximately $424,969,000. Janus Henderson Group PLC increased its holdings in Glaukos by 77.2% in the 1st quarter. Janus Henderson Group PLC now owns 5,348,395 shares of the medical instruments supplier’s stock worth $575,844,000 after acquiring an additional 2,329,608 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its stake in Glaukos by 209.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,350,425 shares of the medical instruments supplier’s stock worth $152,476,000 after acquiring an additional 913,458 shares during the period. 99.04% of the stock is owned by institutional investors.

Glaukos Stock Performance

Shares of GKOS stock opened at $185.66 on Monday. The company has a quick ratio of 4.46, a current ratio of 5.04 and a debt-to-equity ratio of 0.10. The company has a 50 day moving average price of $157.38 and a 200-day moving average price of $131.72. Glaukos has a 52 week low of $73.16 and a 52 week high of $191.62. The firm has a market capitalization of $10.95 billion, a PE ratio of -57.13 and a beta of 0.78.

Glaukos (NYSE:GKOS) last issued its earnings results on Wednesday, July 29th. The medical instruments supplier reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.07. Glaukos had a negative net margin of 30.68% and a negative return on equity of 6.37%. The company had revenue of $185.61 million for the quarter, compared to analysts’ expectations of $150.93 million. During the same quarter last year, the company posted ($0.24) earnings per share. The firm’s quarterly revenue was up 49.6% on a year-over-year basis. As a group, equities research analysts expect that Glaukos will post -0.32 earnings per share for the current year.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.